Form 4: Entrada Therapeutics Director Peter S. Kim Reports Stock Purchases

Director Peter S. Kim of Entrada Therapeutics, Inc. [TRDA] reported the purchase of common stock over three days in March 2024.

Summary

• Peter S. Kim, a director of Entrada Therapeutics, Inc., filed a Form 4 disclosing purchases of the company's common stock.
• The transactions occurred over three days: March 19, 20, and 21, 2024.
• On March 19, Kim purchased 900 shares at a weighted average price of $12.6633.
• On March 20, Kim purchased 1,128 shares at a weighted average price of $12.6604.
• On March 21, Kim purchased 704 shares at a weighted average price of $13.2353.
• Following these transactions, Kim directly owns 49,776 shares of Entrada Therapeutics common stock.

Sentiment

Score: 6

Explanation: Director's stock purchase is a mildly positive signal, suggesting confidence, but the scale of the purchase is not substantial enough to warrant a higher score.

Positives

• A director purchasing company stock can be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. These filings are closely watched by investors seeking insights into management's sentiment and potential future performance.

Stakeholder Impact

• The stock purchases by a director could positively influence shareholder sentiment.

Key Dates